Review - Strategi dan Tantangan Pengembangan Vaksin Demam Berdarah
Keywords:
Demam berdarah dengue (DBD), Virus dengue, Strategi dan Tantangan pengembangan vaksin dengueAbstract
Demam berdarah dengue (DBD) adalah penyakit menular yang ditransmisikan oleh nyamuk Aedes aegypti dan Aedes albopictusyang hidup di negara-negara tropis dan subtropis. Penyakit yang disebabkan oleh virus dengue ini terbagi atas 4 macam serotipe yaitu DENV-1, DENV-2, DENV-3, dan DENV-4. Penelitian ini dilakukan dengan melakukan penelusuran data-data yang berkaitan dengan pengembangan vaksin dengue virus melalui beberapa referensi yang didapat melalui PubMed, Google scholar, Science direct, dan kumpulan jurnal lainnya. Data yang didapat kemudian dikumpulkan dan dibuat menjadi suatu tulisan yang berisi informasi tentang strategi dan  tantangan pengembangan vaksin virus dengue. Berdasarkan data-data yang didapat strategi yang dilakukan dalam menghadapi penyakit DBD adalah dilakukannya penemuan vaksin tetravalent seperti LAV, vaksin Chimera, vaksin Subunit dan vaksin DNA. Uji klinis sampai saat ini masih terus dilakukan untuk mendapatkan kandidat vaksin yang mampu memicu respon imun terhadap keempat serotipe virus dengue. Berdasarkan hal tersebut yang menjadi tantangan dalam pengembangan vaksin tetralaven adalah biaya yang besar dan dan sulitnya menemukan kandidat vaksin dapat memicu respon imun terhadap keempat serotipe tersebut.References
Adnan, Muhammad, Nuhamunada, Matin, Hidayati, Lisna, and Wijayanti, Nastiti. 2020. In silico vaccine design against dengue virus type 2 envelope glycoprotein. Hayati Journal of Biosciences, 27(3): 228–240.
Amin, H.Z., dan Saleha, S. 2013. Perkembangan Mutakhir Vaksin Demam Berdarah. eJKI, 1(3).
Bhamarapravati, N., dan Sutee Y.2000. Live attenuated tetravalent dengue vaccine.Vaccine, 26(18): 44-7.
Bhatt, S., Peter, W.G., Oliver, J. B., Jane, P. M., Andrew, W.F., Cathrine, L.M. 2013. The global distribution and burden of dengue. Nature, 496(7446): 504–5077
Capeding, M.R., Tran, N.H., Hadinegoro, S.R.S., Ismail, Chotpitayasunondh, T., Chua, M.N. 2014. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebocontrolled trial. The Lancet, 384 (9951):1358–65.
Guy, B., Mellanie, S., dan Jean, L. 2010. Development of sanofi pasteur tetravalent dengue vaccine. Human Vaccines, 6(9): 696-705.
Kementrian Kesehatan RI. 2010. Data kasus DBD per bulan di Indonesia tahun 2010, 2009, dan 2008. Jakarta : Departemen Kesehatan RI.
Konishi, E. 2011. Issues related to recent dengue vaccine development. Tropi Medi and Health, 39(4):63-71.
Marbawati, Dewi dan Tri Wijayanti. 2014. Vaksin dengue, tantangan, perkembangan dan strategi. BALABA, 10(01): 39-46.
Guirakhoo, F., Weltzin, R., Chambers, T.J., Zhang, Z.-X., Soike, K., Ratterree, M. 2000. Recombinant Chimeric Yellow Fever-Dengue Type 2 Virus Is Immunogenic and Protective in Nonhuman Primates. Journal of Virology, 74(12):5477– 85.
Khetarpal, Niyati dan Ira Khanna. 2016. Review article dengue fever: causes, complication and vaccine strategies. Journal Of Immunology Research.
Kitchener S, Nissen M, Nasveld P, Forrat R, Yoksan S, Lang J, Saluzzo JF. 2006. Immunogenicity and safety of two liveattenuated tetravalent dengue vaccine formulations in healthy Australian adults.Vaccine, 24(9):1238-41.
Modis, Y., Steven, O., David, C., and Stephen C. H. 2005. Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein. Journal of Virology, 79(2):1223–1231
Meiranty, C. Pangerapan dan Beivy J. Kolondam. 2015. Peran gen struktural, gen non structural dan untranslated region dalam virus dengue. Jurnal Biomedik, 7(2).
Paisal dan Subangkit. 2013. Strategi pengembangan vaksin dengue. Kajian.
Rajapakse, S., Rodrigo, C., dan Rajapakse, A. 2012. Treatment of dengue fever. Infection and Drug Resistance, 103:103–12.
Russell PK, Nisalak A.1967. Dengue virus identification by the plaque reduction neutralization test. J Immunol, 99(2):91-6.
Stephenson, JR. 2005. Understanding dengue pathogenesis: implications for vaccine design. Bull World Health Organ, 83:308-14.
Simmons, P., Farrar, J., Nguyen, V., and Wills, B. 2012. Dengue. New Eng J Med, 366(15):1423-32.
Tang, K.F. and Ooi, E.E. 2012. Diagnosis of dengue: an update. Expert Review of Anti-infective Therapy, 10(8):895–907
Villar, L., Dayan, G.H., Arredondo-GarcÃa, J.L., Rivera, D.M., Cunha, R., Deseda, C. 2015. Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America. New England Journal of Medicine, 372(2):113–123.
Wilder, S.A., Hombach, J., Ferguson, N., Selgelid, M., O’Brien, K., Vannice, K. 2018. Deliberations of the strategic advisory group of experts on immunization on the use of CYD-TDV dengue vaccine. Lancet Infect Dis, 3099(18):3049
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 PHARMACON
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
